Polypharmacy in Elderly Patients With Non-Valvular Atrial Fibrillation　― The Trail to Adverse Events ―

Effect of Polypharmacy on Clinical Outcomes in Elderly Patients With Non-Valvular Atrial Fibrillation　― A Sub-Analysis of the ANAFIE Registry ―

(2022) Takeshi Yamashita et al.   CIRCULATION JOURNAL

Polypharmacy, Adverse Outcomes, and Treatment Effectiveness in Patients ≥75 With Atrial Fibrillation

(2020) Nemin Chen et al.   Journal of the American Heart Association

Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines‐Atrial Fibrillation

(2020) Frederik Dalgaard et al.   Journal of the American Heart Association

Baseline Demographics and Clinical Characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry

(2019) Yukihiro Koretsune et al.   CIRCULATION JOURNAL

Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation

(2017) Shang-Hung Chang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial

(2016) Jeroen Jaspers Focks et al.   BMJ-British Medical Journal

Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial

(2016) Jeroen Jaspers Focks et al.   BMJ-British Medical Journal

Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationCLINICAL PERSPECTIVE

(2015) Jonathan P. Piccini et al.   CIRCULATION

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

(2013) Christian T Ruff et al.   LANCET